Expression of Somatostatin Type 2A Receptor Correlates with Estrogen Receptor in Human Breast Carcinoma

Overview

Journal Endocr Pathol

Specialties Endocrinology
Pathology

Date 2004 Aug 12

PMID 15304840

Citations 4

Authors

M Pilichowska

N Kimura

M Schindler

A Suzuki

R Yoshida

H Nagura

Affiliations

Soon will be listed here.

Abstract

Somatostatin type 2A receptor (sstr2A) has been shown to be directly involved in the transduction of antiproliferative effects and also to be the most predominant sstr subtype in human normal breast epithelium, as well as in human breast carcinoma. We investigated the immunoreactivity of sstr2A in 34 cases of human breast carcinoma and correlated these findings with the immunoreactivity of the estrogen receptor (ER), epidermal growth factor receptor (EGFR), transforming growth factor alpha (TGFalpha) and insulin like growth factor I (IGF-I). We detected sstr2A immunoreactivity in normal mammary tissue, and in 27 of 34 (79%) breast carcinomas. The sstr2A immunoreactivity was localized on the cellular membrane, however, weak cytoplasmic immunoreactivity was also observed. Sstr2A immunoreactivity was heterogenously distributed in the whole tumor section. There was a statistically significant correlation between sstr2A and ER immunoreactivity in the same tumor. No statistically significant correlation was found between sstr2A immunoreactivity and immunoreactivity for EGFR, TGFalpha and IGF-I or the patients' age.

Citing Articles

The Investigation of Somatostatin Receptors as a Potential Target in Breast Phyllodes Tumours.

Suer Mickler H, Erkan M Diagnostics (Basel). 2025; 14(24.

PMID: 39767203 PMC: 11675630. DOI: 10.3390/diagnostics14242841.

International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Gunther T, Tulipano G, Dournaud P, Bousquet C, Csaba Z, Kreienkamp H Pharmacol Rev. 2018; 70(4):763-835.

PMID: 30232095 PMC: 6148080. DOI: 10.1124/pr.117.015388.

Chromogranin A and chromogranin B in noninvasive and invasive breast carcinoma.

Kimura N, Yoshida R, Shiraishi S, Pilichowska M, Ohuchi N Endocr Pathol. 2002; 13(2):117-22.

PMID: 12165659 DOI: 10.1385/ep:13:2:117.

Somatostatin type 2A receptor immunoreactivity in human pancreatic adenocarcinomas.

Pilichowska M, Kimura N, Schindler M, Kobari M Endocr Pathol. 2001; 12(2):147-55.

PMID: 11579680 DOI: 10.1385/ep:12:2:147.

Clinicopathological value of somatostatin type 2A and estrogen receptor immunoreactivity in human breast carcinoma.

Pilichowska M, Kimura N, Suzuki A, Yoshida R, Schindler M, Nagura H Endocr Pathol. 2001; 12(1):55-61.

PMID: 11478269 DOI: 10.1385/ep:12:1:55.

References

Schindler M, Sellers L, Humphrey P, Emson P . Immunohistochemical localization of the somatostatin SST2(A) receptor in the rat brain and spinal cord. Neuroscience. 1997; 76(1):225-40. DOI: 10.1016/s0306-4522(96)00388-0. View

Visser-Wisselaar H, van Uffelen C, Van Koetsveld P, Waaijers A, Uitterlinden P, Mooy D . 17-beta-estradiol-dependent regulation of somatostatin receptor subtype expression in the 7315b prolactin secreting rat pituitary tumor in vitro and in vivo. Endocrinology. 1997; 138(3):1180-9. DOI: 10.1210/endo.138.3.5016. View

Nelson J, Cremin M, Murphy R . Synthesis of somatostatin by breast cancer cells and their inhibition by exogenous somatostatin and sandostatin. Br J Cancer. 1989; 59(5):739-42. PMC: 2247230. DOI: 10.1038/bjc.1989.154. View

Schally A . Oncological applications of somatostatin analogues. Cancer Res. 1988; 48(24 Pt 1):6977-85. View

Lopez F, Esteve J, Buscail L, Delesque N, Saint-Laurent N, Theveniau M . The tyrosine phosphatase SHP-1 associates with the sst2 somatostatin receptor and is an essential component of sst2-mediated inhibitory growth signaling. J Biol Chem. 1997; 272(39):24448-54. DOI: 10.1074/jbc.272.39.24448. View

Smith G, Sharp R, Kordon E, Jhappan C, Merlino G . Transforming growth factor-alpha promotes mammary tumorigenesis through selective survival and growth of secretory epithelial cells. Am J Pathol. 1995; 147(4):1081-96. PMC: 1871019. View

Klapper D, Svoboda M, Van Wyk J . Sequence analysis of somatomedin-C: confirmation of identity with insulin-like growth factor I. Endocrinology. 1983; 112(6):2215-7. DOI: 10.1210/endo-112-6-2215. View

Czech M . Signal transmission by the insulin-like growth factors. Cell. 1989; 59(2):235-8. DOI: 10.1016/0092-8674(89)90281-x. View

Lamberts S, Lely A, de Herder W, Hofland L . Octreotide. N Engl J Med. 1996; 334(4):246-54. DOI: 10.1056/NEJM199601253340408. View

10.

Fisher W, Muscarella P, ODorisio T, ODorisio M, Kim J, Doran T . Expression of the somatostatin receptor subtype-2 gene predicts response of human pancreatic cancer to octreotide. Surgery. 1996; 120(2):234-40; discussion 240-1. DOI: 10.1016/s0039-6060(96)80293-5. View

11.

van Agthoven T, Timmermans M, Dorssers L, Henzen-Logmans S . Expression of estrogen, progesterone and epidermal growth factor receptors in primary and metastatic breast cancer. Int J Cancer. 1995; 63(6):790-3. DOI: 10.1002/ijc.2910630607. View

12.

Janson E, Gobl A, Kalkner K, Oberg K . A comparison between the efficacy of somatostatin receptor scintigraphy and that of in situ hybridization for somatostatin receptor subtype 2 messenger RNA to predict therapeutic outcome in carcinoid patients. Cancer Res. 1996; 56(11):2561-5. View

13.

Lippman M, Dickson R, Gelmann E, Rosen N, Knabbe C, Bates S . Growth regulation of human breast carcinoma occurs through regulated growth factor secretion. J Cell Biochem. 1987; 35(1):1-16. DOI: 10.1002/jcb.240350102. View

14.

Buscail L, Delesque N, Esteve J, Saint-Laurent N, Prats H, Clerc P . Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc Natl Acad Sci U S A. 1994; 91(6):2315-9. PMC: 43361. DOI: 10.1073/pnas.91.6.2315. View

15.

Henkelman M, Foekens J, Klijn G . Direct inhibitory effects of somatostatin (analogues) on the growth of human breast cancer cells. Cancer Res. 1987; 47(6):1566-70. View

16.

Weckbecker G, Tolcsvai L, Stolz B, Pollak M, Bruns C . Somatostatin analogue octreotide enhances the antineoplastic effects of tamoxifen and ovariectomy on 7,12-dimethylbenz(alpha)anthracene-induced rat mammary carcinomas. Cancer Res. 1994; 54(24):6334-7. View

17.

Foekens J, Portengen H, van Putten W, Trapman A, Reubi J, Klijn J . Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res. 1989; 49(24 Pt 1):7002-9. View

18.

Yamada Y, Kagimoto S, Kubota A, Yasuda K, Masuda K, Someya Y . Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and a fifth (hSSTR5) human somatostatin receptor subtype. Biochem Biophys Res Commun. 1993; 195(2):844-52. DOI: 10.1006/bbrc.1993.2122. View

19.

Yee D, Paik S, Lebovic G, Marcus R, Favoni R, Cullen K . Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol Endocrinol. 1989; 3(3):509-17. DOI: 10.1210/mend-3-3-509. View

20.

Schaer J, Waser B, Mengod G, Reubi J . Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography. Int J Cancer. 1997; 70(5):530-7. DOI: 10.1002/(sici)1097-0215(19970304)70:5<530::aid-ijc7>3.0.co;2-z. View